AU2015240519B2 - Substituted spirocyclic inhibitors of autotaxin - Google Patents

Substituted spirocyclic inhibitors of autotaxin Download PDF

Info

Publication number
AU2015240519B2
AU2015240519B2 AU2015240519A AU2015240519A AU2015240519B2 AU 2015240519 B2 AU2015240519 B2 AU 2015240519B2 AU 2015240519 A AU2015240519 A AU 2015240519A AU 2015240519 A AU2015240519 A AU 2015240519A AU 2015240519 B2 AU2015240519 B2 AU 2015240519B2
Authority
AU
Australia
Prior art keywords
methyl
decan
fluoro
triazaspiro
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015240519A
Other languages
English (en)
Other versions
AU2015240519A1 (en
Inventor
Lee BABISS
Matthew Clark
Anthony D. Keefe
Mark J. Mulvihill
Haihong Ni
Louis RENZETTI
Frank Ruebsam
Ce Wang
Zhifeng Xie
Ying Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
X-RX Inc
Original Assignee
X RX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X RX Inc filed Critical X RX Inc
Publication of AU2015240519A1 publication Critical patent/AU2015240519A1/en
Application granted granted Critical
Publication of AU2015240519B2 publication Critical patent/AU2015240519B2/en
Priority to AU2019264641A priority Critical patent/AU2019264641A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2015240519A 2014-04-04 2015-04-03 Substituted spirocyclic inhibitors of autotaxin Ceased AU2015240519B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019264641A AU2019264641A1 (en) 2014-04-04 2019-11-15 Substituted spirocyclic inhibitors of autotaxin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461975123P 2014-04-04 2014-04-04
US61/975,123 2014-04-04
PCT/US2015/024338 WO2015154023A1 (en) 2014-04-04 2015-04-03 Substituted spirocydic inhibitors of autotaxin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019264641A Division AU2019264641A1 (en) 2014-04-04 2019-11-15 Substituted spirocyclic inhibitors of autotaxin

Publications (2)

Publication Number Publication Date
AU2015240519A1 AU2015240519A1 (en) 2016-10-20
AU2015240519B2 true AU2015240519B2 (en) 2019-08-15

Family

ID=54241341

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015240519A Ceased AU2015240519B2 (en) 2014-04-04 2015-04-03 Substituted spirocyclic inhibitors of autotaxin
AU2019264641A Abandoned AU2019264641A1 (en) 2014-04-04 2019-11-15 Substituted spirocyclic inhibitors of autotaxin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019264641A Abandoned AU2019264641A1 (en) 2014-04-04 2019-11-15 Substituted spirocyclic inhibitors of autotaxin

Country Status (21)

Country Link
US (3) US10011601B2 (enExample)
EP (1) EP3125895A4 (enExample)
JP (2) JP6616821B2 (enExample)
KR (1) KR20160133004A (enExample)
CN (1) CN107106559A (enExample)
AP (1) AP2016009496A0 (enExample)
AU (2) AU2015240519B2 (enExample)
CA (1) CA2943874A1 (enExample)
CL (1) CL2016002516A1 (enExample)
CR (1) CR20160496A (enExample)
CU (1) CU24442B1 (enExample)
DO (1) DOP2016000270A (enExample)
EA (1) EA201691840A1 (enExample)
EC (1) ECSP16084293A (enExample)
IL (1) IL248050A0 (enExample)
MD (1) MD20160116A2 (enExample)
MX (1) MX2016013049A (enExample)
PE (1) PE20170206A1 (enExample)
PH (1) PH12016501922A1 (enExample)
SG (1) SG11201607920RA (enExample)
WO (1) WO2015154023A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013186159A1 (en) 2012-06-13 2013-12-19 F. Hoffmann-La Roche Ag New diazaspirocycloalkane and azaspirocycloalkane
HRP20191937T1 (hr) 2012-09-25 2020-01-10 F. Hoffmann - La Roche Ag Derivati heksahidropirolo [3,4-c]pirola i srodni spojevi kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za liječenje npr. bubrežnih bolesti
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
RS56776B1 (sr) 2013-11-26 2018-04-30 Hoffmann La Roche Derivati oktahidro-ciklobuta [1,2-c;3,4-c']dipirola kao inhibitori autotaksina
CA2935612A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
UA118582C2 (uk) 2014-03-26 2019-02-11 Ф. Хоффманн-Ля Рош Аг Біциклічні сполуки як інгібітори продукції аутотаксину (atx) і лізофосфатидилової кислоти (lpa)
WO2015154023A1 (en) 2014-04-04 2015-10-08 X-Rx Discovery, Inc. Substituted spirocydic inhibitors of autotaxin
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CR20180058A (es) 2015-09-04 2018-02-26 Hoffmann La Roche Nuevos derivados de fenoximetilo
BR112017026682A2 (pt) 2015-09-24 2018-08-14 Hoffmann La Roche novos compostos bicíclicos como inibidores de dupla ação de atx/ca
EP3353176B1 (en) 2015-09-24 2022-01-19 F. Hoffmann-La Roche AG Bicyclic compounds as atx inhibitors
EP3353180B1 (en) 2015-09-24 2022-03-16 F. Hoffmann-La Roche AG Bicyclic compounds as atx inhibitors
PE20180552A1 (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca
CA3016081A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
JOP20190107A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN108456208B (zh) * 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
BR112019019017A2 (pt) 2017-03-16 2020-04-14 Hoffmann La Roche compostos heterocíclicos de utilidade como inibidores duplos de atx/ca
US10961242B2 (en) 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
EP3689879B1 (en) 2017-09-29 2025-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2020051230A1 (en) * 2018-09-04 2020-03-12 X-Rx, Inc. Amorphous pharmaceutical compositions and uses thereof
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
BR112023002031A2 (pt) * 2020-08-14 2023-03-07 Novartis Ag Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
UY39516A (es) 2020-11-13 2022-05-31 H Lundbeck As Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
CN112675308B (zh) * 2020-12-09 2023-05-05 中国人民解放军军事科学院军事医学研究院 抑制enpp2基因和/或蛋白表达的物质在制备治疗多发性骨髓瘤的药物中的应用
EP4599849A3 (en) 2021-01-05 2025-10-22 Zydus Lifesciences Limited Novel inhibitors of autotaxin
WO2023213854A1 (en) 2022-05-04 2023-11-09 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.
EP4594320A1 (en) * 2022-09-30 2025-08-06 Genentech Inc. Hydantoin modulators of cholesterol biosynthesis and their use for promoting remyelination

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070511A1 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
WO2002069905A2 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
WO2010037081A1 (en) * 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877182A (en) 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
BR9808502A (pt) 1997-05-08 2000-05-23 Smithkline Beecham Corp Inibidores de protease
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
PL369337A1 (en) * 2001-10-01 2005-04-18 Bristol-Myers Squibb Company Spiro-hydantoin compounds useful as anti-inflammatory agents
US20040192674A1 (en) 2003-02-14 2004-09-30 Marquis Robert W. Cathepsin L inhibitors
EP1599447A1 (en) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
WO2005122379A2 (en) * 2004-05-27 2005-12-22 The Regents Of The University Of California Alpha-4 beta-1 integrin ligands for imaging and therapy
JPWO2006137465A1 (ja) 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8906859B2 (en) * 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
CN101534824A (zh) 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
US8378100B2 (en) 2008-01-09 2013-02-19 University Of Virginia Patent Foundation Phosphonate derivatives as autotaxin inhibitors
AU2009225441B2 (en) 2008-03-20 2012-12-13 Forest Laboratories Holdings Limited Novel piperidine derivatives as inhibitors of stearoyl-CoA desaturase
WO2009151644A2 (en) 2008-06-13 2009-12-17 Yale University Small molecule inhibitors of autotaxin methods of use
EP2352732B1 (en) 2008-12-01 2013-02-20 Merck Patent GmbH 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER
EP2414327B1 (de) 2009-04-02 2014-11-19 Merck Patent GmbH Heterocyclische verbindungen als autotaxin-inhibitoren
JP5591318B2 (ja) 2009-04-02 2014-09-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング オートタキシン阻害剤としてのピペリジンおよびピペラジン誘導体
CA2757415C (en) 2009-04-02 2018-02-06 Merck Patent Gmbh Autotaxin inhibitors
ES2414934T3 (es) * 2009-06-11 2013-07-23 Abbvie Bahamas Limited Inhibidores del virus de la Hepatitis C
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
CN102574822A (zh) 2009-08-04 2012-07-11 阿米拉制药公司 作为溶血磷脂酸受体拮抗剂的化合物
KR101184115B1 (ko) * 2009-08-31 2012-09-18 일동제약주식회사 신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법
US8497371B2 (en) 2009-10-26 2013-07-30 University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
EP2552914B1 (de) 2010-03-26 2015-11-11 Merck Patent GmbH Benzonaphthyridinamine als autotaxin-inhibitoren
JP2011219368A (ja) 2010-04-02 2011-11-04 Daiichi Sankyo Co Ltd Ｎ−サリチルアミノ酸誘導体
WO2012024620A2 (en) 2010-08-20 2012-02-23 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
EP2714680B1 (en) 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
US8546416B2 (en) * 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
WO2013061297A1 (en) 2011-10-28 2013-05-02 Pfizer Limited Pyridazine Derivatives Useful in Therapy
WO2013186159A1 (en) 2012-06-13 2013-12-19 F. Hoffmann-La Roche Ag New diazaspirocycloalkane and azaspirocycloalkane
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
TW201500356A (zh) 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物
EP3022201A1 (en) 2013-07-18 2016-05-25 Novartis AG Autotaxin inhibitors
AP2016009020A0 (en) 2013-07-18 2016-02-29 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
EP3046905A4 (en) 2013-09-17 2017-03-22 Pharmakea Inc. Vinyl autotaxin inhibitor compounds
JP2016530210A (ja) 2013-09-17 2016-09-29 ファーマケア，インク． ヘテロ環式ビニルオートタキシン阻害剤化合物
WO2015048301A1 (en) 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds
WO2015154023A1 (en) 2014-04-04 2015-10-08 X-Rx Discovery, Inc. Substituted spirocydic inhibitors of autotaxin
WO2015175171A1 (en) 2014-04-23 2015-11-19 X-Rx Discovery, Inc. Substituted n-(2-(amino)-2-oxoethyl)benzamide inhibitors of autotaxin and their preparation and use in the treatment of lpa-dependent or lpa-mediated diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070511A1 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
WO2002069905A2 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
WO2010037081A1 (en) * 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2000-11-15), URL: STN *

Also Published As

Publication number Publication date
IL248050A0 (en) 2016-11-30
SG11201607920RA (en) 2016-10-28
WO2015154023A1 (en) 2015-10-08
AP2016009496A0 (en) 2016-10-31
CA2943874A1 (en) 2015-10-08
US10011601B2 (en) 2018-07-03
US10233182B2 (en) 2019-03-19
JP6616821B2 (ja) 2019-12-04
MX2016013049A (es) 2017-04-27
PE20170206A1 (es) 2017-04-09
KR20160133004A (ko) 2016-11-21
CU20160150A7 (es) 2017-02-02
US20170166568A1 (en) 2017-06-15
CN107106559A (zh) 2017-08-29
EA201691840A1 (ru) 2017-03-31
CU24442B1 (es) 2019-09-04
MD20160116A2 (ro) 2017-04-30
US20180282332A1 (en) 2018-10-04
PH12016501922A1 (en) 2016-12-19
AU2019264641A1 (en) 2019-12-05
EP3125895A4 (en) 2017-08-30
JP2020040960A (ja) 2020-03-19
CL2016002516A1 (es) 2017-05-12
CR20160496A (es) 2017-01-02
EP3125895A1 (en) 2017-02-08
AU2015240519A1 (en) 2016-10-20
JP2017513932A (ja) 2017-06-01
US20190225611A1 (en) 2019-07-25
ECSP16084293A (es) 2017-01-31
DOP2016000270A (es) 2016-12-15

Similar Documents

Publication Publication Date Title
AU2015240519B2 (en) Substituted spirocyclic inhibitors of autotaxin
JP6592008B2 (ja) オートタキシンの置換ｎ−（２−アミノ）−２−オキソエチルベンズアミド阻害剤およびそれらの調製、ならびにｌｐａ依存性またはｌｐａ媒介性疾患の処置における使用
AU2017311645B2 (en) Pyridopyrimdinone CDK2/4/6 inhibitors
JP7112488B2 (ja) タンパク質キナーゼ阻害剤としての複素環化合物
JP2011520896A (ja) キナーゼ阻害剤としてのピロロピリジン
UA114323C2 (uk) Інгібітори nampt
JP2023509495A (ja) ＲＯＲγｔ阻害剤、その製造方法及び使用
CA3219215A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
TW202122382A (zh) 乙內醯脲衍生物
JP6322275B2 (ja) ヤヌスキナーゼ阻害剤としてのｎ−（２−シアノヘテロシクリル）ピラゾロピリドン
AU2020400010A1 (en) Heterocyclic compounds as modulators of Stimulator of Interferon Genes (STING)
TW202146384A (zh) 取代的氮雜五元環類化合物及其在藥物中的應用
KR102133595B1 (ko) 단백질 키나제 억제제로서의 헤테로고리 화합물
WO2019013562A1 (ko) 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
OA18996A (en) Substituted Spirocyclic Inhibitors of Autotaxin
KR102112336B1 (ko) 단백질 키나제 억제제로서의 헤테로고리 화합물
RU2783723C2 (ru) Гетероциклическое соединение в качестве ингибитора протеинкиназы
JP7061663B2 (ja) 新規な１ｈ－ピラゾロピリジン誘導体およびこれを含む薬学組成物
WO2024086094A1 (en) Alkylamine-containing small molecule degraders of bcl6
NZ787918A (en) Pyridopyrimdinone CDK2/4/6 inhibitors
EA041386B1 (ru) Спироциклические соединения и способы их получения и применения

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired